Ignyte Acquisition (Ignyte Acquisition) Cash, Cash Equivalents, Marketable Securities : $0.05 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ignyte Acquisition Cash, Cash Equivalents, Marketable Securities?

Ignyte Acquisition's quarterly cash, cash equivalents, marketable securities declined from Dec. 2021 ($0.33 Mil) to Mar. 2022 ($0.21 Mil) but then stayed the same from Mar. 2022 ($0.21 Mil) to Jun. 2022 ($0.05 Mil).

Ignyte Acquisition's annual cash, cash equivalents, marketable securities increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.03 Mil) and increased from Dec. 2020 ($0.03 Mil) to Dec. 2021 ($0.33 Mil).

Ignyte Acquisition Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Ignyte Acquisition's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyte Acquisition Cash, Cash Equivalents, Marketable Securities Chart

Ignyte Acquisition Annual Data

Trend

Dec20

Dec21

Cash, Cash Equivalents, Marketable Securities

0.03

0.33

Ignyte Acquisition Quarterly Data
	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			0.55	0.53	0.33	0.21	0.05

Ignyte Acquisition Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Ignyte Acquisition (NAS:IGNY) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Ignyte Acquisition Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ignyte Acquisition's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ignyte Acquisition (Ignyte Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ignyte Acquisition Corp (NAS:IGNY) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

640 5th Avenue, 4th Floor, New York, NY, USA, 10019

Website

https://ignytespac.com

Ignyte Acquisition Corp is a blank check company.

Executives

Richard J Rosenstock	director	C/O GAINES BERLAND INC, 1055 STEWART AVENUE, BETHPAGE NY 11714
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Charles Wilson	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Ignyte Sponsor Llc	10 percent owner	640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019
David I. Rosenberg	director, 10 percent owner, officer: Co-Chief Executive Officer	C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019
John Andrew Boockvar	director	C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019
David J. Strupp	director, 10 percent owner, officer: Co-Chief Executive Officer	107 DUNNING ROAD, NEW CANAAN CT 06840
Steven Neil Kaplan	director, officer: Chief Financial Officer	C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017